Biomarker Insights
Synopsis: An open access, peer reviewed electronic journal that covers all aspects of biomarker research and clinical applications.
Indexing: Pubmed, Pubmed Central, EBSCO Academic Research Complete, Embase, Embiology, SCOPUS, Google Scholar, CAS, DOAJ, OAIster.
Processing time: Decision in 2 weeks for 90% of papers.
Visibility: Most popular article read 1400+ times.
About this journal
Aims and scope:
Biomarker Insights is a peer-reviewed, open-access research journal where those engaged in biomarker research can turn for rapid communication of the latest advances in the application of biomarkers toward the discovery of new knowledge, and toward the clinical translation of that knowledge to increase the efficacy of practicing clinicians. Papers submitted for review in Biomarker Insights should focus on the following areas:
- Biomarkers as tools in decision making
- Regulatory acceptance of biomarkers
- Biomarker development and validation
- Role of collaborations and consortia in biomarker advancement
- The "Economics" Behind Personalized Medicine and Pharmacogenomics
- Toxicity biomarkers, toxicogenomics
- Biomarkers for early efficacy assessment
- Genetic biomarkers; genomic biomarkers
- Protein biomarkers
- Metabolomic biomarkers
- Pathway analysis
- Biomarkers in clinical pharmacology
- Biomarkers for clinical safety assessment
- Clinical pharmacogenomics
- Biomarkers to monitor and predict disease progression and response to therapy
- Clinical validation of biomarkers
- Patient selection
- Biomarkers as surrogate end-points
- Biomarkers as indications for drug therapy
- Biomarker assay development and validation
- Outcome diagnostics
- Cancer diagnostics
- Monitoring response to therapy
- Discovery-to-Diagnostic translation
- Clinical Proteomics: potential of proteomic technologies in diagnostics
- Expression signatures as diagnostic/prognostic tools
- Imaging biomarkers pharmacodiagnostics, companion diagnostics
- Integration of biomarkers into clinical practice guidelines and clinical decision support systems
- Integration of biomarkers into mathematical models and algorithms
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by the following services:
- Pubmed
- Pubmed Central
- EBSCO Academic Research Complete
- Embase
- Embiology
- SCOPUS
- Google Scholar
- CAS
- DOAJ
- OAIster
SPARC Europe Seal award winner:
This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.
Amongst other important services DOAJ makes metadata OAI-compliant. This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource. The DOAJ search page is available here.
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
Read the Editor in Chief's latest call for papers here.Submission types accepted:
Submissions of the following types of manuscripts are accepted:
- Original research articles.
- Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
- Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
- Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
- Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
- Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Short reports: brief reports of data from original research.
- Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
- Have your paper's reference style revised to meet our requirements,
- Have your paper's English revised by specialist English-speaking technical editors.
After peer review of your paper we can:
- Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
- Provide bound reprints of your article in colour or black and white ,
- Provide online-early rapid publication if your paper prior to typesetting.
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
All submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
Journal newsletter sent to subscribers in week 33, 2009. Register to receive future newsletters.
Biomarker Insights is now indexed by Pubmed
Journal newsletter sent to subscribers in week 31, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 30, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 29, 2009. Register to receive future newsletters.
Read an interview with Associate Editor Dr Karen Pulford
Read the Editor in Chief's call for papers
Journal newsletter sent to subscribers in week 26, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 23, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 20, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 19, 2009. Register to receive future newsletters.
Follow this journal on Twitter
Journal newsletter sent to subscribers in week 13, 2009. Register to receive future newsletters.
The journal has been accepted for indexing in EBSCO Academic Search Complete.
New call for papers sent to newsletter subscribers in week 10 2009. Readers who wish to be elligible to receive CFPs should subscribe to the newsletter.
Journal newsletter sent to subscribers in week 8, 2009. Register to receive future newsletters.
Journal newsletter sent to subscribers in week 7, 2009. Register to receive future newsletters.
Peer reviewers are sought. Click here to apply or to update your details.
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer
Giannis Mountzios, Meletios-Athanasios Dimopoulos and Christos Papadimitriou
Medical Oncology Unit, Department of Clinical Therapeutics, University Hospital Alexandra, Athens, Greece.
Abstract
Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all patients derive clinical benefit from such a treatment. Hence, the development of predictive biomarkers able to identify lung cancer patients who are most likely to benefit from cisplatin-based chemotherapy has become a scientific priority. Among the molecular pathways involved in DNA damage control after chemotherapy, the nucleotide excision repair (NER) is a critical process for the repair of DNA damage caused by cisplatin-induced DNA adducts. Many reports have explored the role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells.
Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in chemo-naïve patients. On the contrary, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. In a prospective cohort studying mRNA expression in tumor biopsies from patients receiving customized therapy with cisplatin and gemcitabine depending on the molecular profile of the tumour, results showed that patients with low ERCC1 mRNA expression had a longer median survival compared to those with high expression. These data suggest the potent use of ERCC1 as a molecular predictor of clinical resistance to platinum-based chemotherapy in the adjuvant setting of NSCLC. Nevertheless, optimization of methodology, including standardization of technical procedures, as well as validation of ERCC1 protein expression in large prospective cohorts, seem necessary before any routine immunohistochemical validation of ERCC1 can be implemented in daily practice.
Readers of this also read:
- The Role of Thrombospondin 1 on Intestinal Inflammation and Carcinogenesis
- Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future
- What is New on Thyroid Cancer Biomarkers
- Time Dependent Gene Expression Changes in the Liver of Mice Treated with Benzene
- DICER1 and PRKRA in Colon Adenocarcinoma
- 05/Aug/2009
Joint Variable Selection and Classification with Immunohistochemical Data
- 22/Jul/2009
Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy
- 23/Jun/2009
Pathway Analysis of Differentially Expressed Genes in Patients with Acute Aortic Dissection
- 06/May/2009
Investigating Multi-cancer Biomarkers and Their Cross-predictability in the Expression Profiles of Multiple Cancer Types
- 01/May/2009
Plasma Carotenoids and Biomarkers of Oxidative Stress in Patients with prior Head and Neck Cancer
- 23/Mar/2009
Low Serum Alpha-1 Antitrypsin (AAT) in Family Members of Individuals with Autism Correlates with PiMZ Genotype
- 18/Mar/2009
Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis
- 17/Feb/2009
Breath Hydrogen Produced by Ingestion of Commercial Hydrogen Water and Milk
- 09/Feb/2009
Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells
- 08/Jul/2008
Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy (Provisional PDF)
- 15/Jan/2009
Breath Hydrogen Gas Concentration Linked to Intestinal Gas Distribution and Malabsorption in Patients with Small-bowel Pseudo-obstruction
- 15/Jan/2009
Gene Expression in Hair Follicle Dermal Papilla Cells after Treatment with Stanozolol
- 23/Dec/2008
Biomarkers in Acute Coronary Syndrome
- 05/Nov/2008
Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen
- 23/Sep/2008
Clinical Performance of a Salivary Amylase Activity Monitor During Hemodialysis Treatment
- 15/Sep/2008
Hematopoietic Lineage Transcriptome Stability and Representation in PAXgeneTM Collected Peripheral Blood Utilising SPIA Single-Stranded cDNA Probes for Microarray
- 25/Aug/2008
Pulmonary Biomarkers of Bronchopulmonary Dysplasia
- 02/Jul/2008
Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk
- 02/Jul/2008
Tracking Differential Gene Expression in MRL/MpJ Versus C57BL/6 Anergic B Cells: Molecular Markers of Autoimmunity
- 10/Jun/2008
Proteomics Discovery of Disease Biomarkers
- 06/Jun/2008
Activation of Tissue Remodeling Precedes Obliterative Bronchiolitis in Lung Transplant Recipients
- 06/Jun/2008
Alzheimer’s Disease, Diagnosis and the Need for Biomarkers
- 27/May/2008
Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia
- 27/May/2008
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future
- 19/May/2008
MUC1 as a Putative Prognostic Marker for Prostate Cancer
- 14/May/2008
Changes in Hyaluronan Metabolism and RHAMM Receptor Expression Accompany Formation of Complicated Carotid Lesions and May be Pro-Angiogenic Mediators of Intimal Neovessel Growth
- 12/May/2008
What is New on Thyroid Cancer Biomarkers
- 29/Apr/2008
DICER1 and PRKRA in Colon Adenocarcinoma
- 28/Apr/2008
A Rapid and Simple Bioassay Method for Herbicide Detection
- 28/Apr/2008
Dendritic Cells Promoted by Ginseng Saponins Drive a Potent Th1 Polarization
- 18/Apr/2008
Comparison of the Calibration Standards of Three Commercially Available Multiplex Kits for Human Cytokine Measurement to WHO Standards Reveals Striking Differences
- 18/Apr/2008
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer
- 17/Apr/2008
Biomarkers of Ovarian Reserve
- 16/Apr/2008
Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review
- 10/Apr/2008
The Role of Thrombospondin 1 on Intestinal Inflammation and Carcinogenesis
- 28/Mar/2008
Time Dependent Gene Expression Changes in the Liver of Mice Treated with Benzene
- 28/Mar/2008
Chemical Biomarkers of Human Breast Milk Pollution
- 28/Mar/2008
Useulness of B Natriuretic Peptides and Procalcitonin in Emergency Medicine
- 27/Mar/2008
FTIR Microspectroscopy Coupled with Two-Class Discrimination Segregates Markers Responsible for Inter- and Intra-Category Variance in Exfoliative Cervical Cytology
- 25/Mar/2008
Serum and Ascitic Fluid Superoxide Dismutase and Malondialdehyde Levels in Patients with Cirrhosis
- 12/Mar/2008
Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice
- 12/Mar/2008
Proteomic Biomarkers of Atherosclerosis
- 12/Mar/2008
An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease
- 01/Mar/2008
Repeatedly Heading a Soccer Ball Does Not Increase Serum Levels of S-100B, a Biochemical Marker of Brain Tissue Damage: an Experimental Study
- 29/Feb/2008
Biomarkers in Acute Kidney Injury
- 26/Feb/2008
Cellular Adhesion Molecules in Healthy Subjects: Short Term Variations and Relations to Flow Mediated Dilation
- 14/Feb/2008
Expression of Osteoarthritis Marker YKL-39 is Stimulated by Transforming Growth Factor Beta (TGF-beta) and IL-4 in Differentiating Macrophages
- 14/Feb/2008
Genomic and Proteomic Biomarker Discovery in Neurological Disease
- 09/Feb/2008
Candidate List of yoUr Biomarker (CLUB): A Web-based Platform to Aid Cancer Biomarker Research
- 09/Feb/2008
Sample Stability and Protein Composition of Saliva: Implications for Its Use as a Diagnostic Fluid
- 01/Feb/2008
Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer
- 01/Feb/2008
Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone
- 25/Jan/2008
DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
- 25/Jan/2008
Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma
- 21/Jan/2008
Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis
- 18/Dec/2007
Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling
- 11/Dec/2007
Clastogenic Factors as Potential Biomarkers of Increased Superoxide Production
- 11/Dec/2007
An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study
- 11/Dec/2007
Genetic Alterations in Pesticide Exposed Bolivian Farmers: An evaluation by analysis of chromosomal aberrations and the comet assay
- 12/Nov/2007
Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas
- 11/Nov/2007
The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer
- 05/Nov/2007
Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection
- 16/Oct/2007
Endogenous Plasma Peptide Detection and Identification in the Rat by a Combination of Fractionation Methods and Mass Spectrometry
- 09/Oct/2007
Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction
- 08/Oct/2007
Recursive Partitioning Analysis of Mediastinal N2 Lymph Node Involvement with Selected Biological Markers in Operable Non-small Cell Lung Cancer: A Correlative Study
- 06/Oct/2007
Proteomics and Mass Spectrometry for Cancer Biomarker Discovery
- 03/Oct/2007
Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases
- 17/Sep/2007
Electron Pathways through Erythrocyte Plasma Membrane in Human Physiology and Pathology: Potential Redox Biomarker?
- 17/Sep/2007
Genome-Wide Association Studies: Progress in Identifying Genetic Biomarkers in Common, Complex Diseases
- 08/Aug/2007
Studies of Wilms’ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore
- 08/Aug/2007
Alteration of Transthyretin Microheterogeneity in Serum of Multiple Trauma Patients
- 08/Aug/2007
Determination of Tobacco Specific Hemoglobin Adducts in Smoking Mothers and New Born Babies by Mass Spectrometry
- 06/Aug/2007
Soluble CD26 is inversely Associated with Disease Severity in Patients with Chronic Eosinophilic Pneumonia
- 07/Feb/2007
Multianalyte Tests for the Early Detection of Cancer: Speedbumps and Barriers
- 10/Jul/2007
Biomarker Discovery in Animal Health and Disease: The Application of Post-Genomic Technologies
- 10/Jul/2007
Gene Expression Profiles from Needle Biopsies Provide Useful Signatures of Non-Small Cell Lung Carcinomas
- 08/Jun/2007
Mouse Germ Cell Development in-vivo and in-vitro
- 06/Jun/2007
Protein Tyrosine Phosphatase Gamma (PTPγ) is a Novel Leukocyte Marker Highly Expressed by CD34+ Precursors
- 31/May/2007
TLR2 and TLR4 as Potential Biomarkers of Environmental Particulate Matter Exposed Human Myeloid Dendritic Cells
- 30/May/2007
Expression of Cancer-Associated Molecules in Malignant Mesothelioma
- 30/May/2007
Molecular Markers for Biomass Traits: Association, Interaction and Genetic Divergence in Silkworm Bombyx mori
- 30/May/2007
The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
- 03/May/2007
Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer
- 03/May/2007
Ubiquitin Fusion Degradation Protein 1 as a Blood Marker for The Early Diagnosis of Ischemic Stroke
- 19/Apr/2007
Evaluation of Tissue Metabolites with High Resolution Magic Angle Spinning MR Spectroscopy Human Prostate Samples After Three-Year Storage at -80 ºC
- 18/Apr/2007
The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients
- 03/Apr/2007
Changes in Metallothionein Levels in Freshwater Mussels Exposed to Urban Wastewaters: Effects from Exposure to Heavy Metals?
- 29/Mar/2007
Biomarkers in Bladder Cancer: Present Status and Perspectives
- 27/Mar/2007
Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I: Comparison between Healthy Subjects and Patients with Hypertension
- 22/Mar/2007
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells
- 02/Mar/2007
Clinical Significance of Telomere Length and Associated Proteins in Oral Cancer
- 14/Feb/2007
Methodology and Applications of Disease Biomarker Identification in Human Serum
- 14/Feb/2007
Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field
- 14/Feb/2007
Microvessel Density and Clinicopathologic Characteristics in Hepatocellular Carcinoma With and Without Cirrhosis
- 14/Feb/2007
Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia
- 14/Feb/2007
Evaluation of Cellular Fibronectin Plasma Levels as a Useful Staging Tool in Different Stages of Transitional Cell Carcinoma of the Bladder and Renal Cell Carcinoma
- 07/Feb/2007
Biomarkers in Cervical Cancer
- 07/Feb/2007
Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients
- 07/Feb/2007
Comparison of Apoptosis Detection Markers Combined with Macrophage Immunostaining to Study Phagocytosis of Apoptotic Cells in Situ
- 07/Feb/2007